Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 8:2020:2808413.
doi: 10.1155/2020/2808413. eCollection 2020.

Intracytoplasmic Expression of IL-6 and IL-17A in Circulating CD4+ T Cells Are Strongly Associated with and Predict Disease Activity in Rheumatoid Arthritis: A Case-Control Study in Ghana

Affiliations

Intracytoplasmic Expression of IL-6 and IL-17A in Circulating CD4+ T Cells Are Strongly Associated with and Predict Disease Activity in Rheumatoid Arthritis: A Case-Control Study in Ghana

Samuel Asamoah Sakyi et al. Int J Rheumatol. .

Abstract

Background: T cell cytokines play important roles in the development and progression of rheumatoid arthritis (RA). Loss of Th1/Th2 and Th17/Treg balance has been reported in several inflammatory autoimmune diseases. However, their role in RA within hitherto rare Ghanaian context has not been explored. Here, we evaluated the intracytoplasmic CD4+ T cell cytokine patterns in rheumatoid arthritis patients in Ghana and determined their relationship with disease activity.

Methods: This case-control study included 48 newly diagnosed RA patients and 30 apparent healthy controls from two major hospitals in Ghana. Validated structured questionnaires were administered to obtain demographic data; blood samples were collected and processed for flow cytometric analysis.

Results: IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, IL-6/IL-4, and IL-17/IL-10 expressions were significantly higher in RA cases compared to the healthy controls. The expression of IL-6 (0.00 (0.00-0.98) vs. 0.82 (0.34-1.10) vs. 1.56 (1.39-1.68), p < 0.0001), IL-17A (0.00 (0.00-0.02) vs. 0.19 (0.09-0.30) vs. 0.99 (0.64-1.25), p < 0.0001), and IL-17A/IL-10 (0.00 (0.00-0.39) vs. 0.15 (0.09-0.26) vs. 0.88 (0.41-1.47), p < 0.0001) increased significantly from the healthy controls through RA patients with low DAS scores to RA patients with moderate DAS scores. IL-6 (β = 0.681, r 2 = 0.527, p < 0.0001), IL-17A (β = 0.770, r 2 = 0.593, p < 0.0001), and IL-17A/IL-10 (β = 0.677, r 2 = 0.452, p < 0.0001) expressions were significantly directly associated with DAS28 scores. IL-6 (cutoff = 1.32, sensitivity = 100.0%, specificity = 100.0%, accuracy = 100.0%, and AUC = 1.000) and IL-17A (cutoff = 0.58, sensitivity = 100.0%, specificity = 100.0%, accuracy = 100.0%, and AUC = 1.000) presented with the best discriminatory power in predicting moderate DAS scores from low DAS scores.

Conclusion: Th1- and Th17-related cytokines predominate in the pathophysiology of RA, with IL-6 and IL-17 being principally and differentially expressed based on the severity of the disease. IL-6 and IL-17A could serve as useful prognostic and disease-monitoring markers in RA in the African context.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Comparison of T cell cytokines and their ratios between RA cases and healthy controls. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.0001.
Figure 2
Figure 2
Comparison of T cell cytokines and their ratios between healthy controls and RA cases based on DAS28 scores. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.0001.
Figure 3
Figure 3
Linear relationship between T cell cytokines and their ratios and DAS28 scores among RA patients.
Figure 4
Figure 4
Performance of selected T cell cytokines to discriminate low and moderate DAS scores in RA. Test direction is negative (smaller test results indicate presence of condition).

Similar articles

Cited by

References

    1. Abdel-Nasser A. M., Rasker J. J., Valkenburg H. A. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 1997;27(2):123–140. doi: 10.1016/s0049-0172(97)80012-1. - DOI - PubMed
    1. Chen J., Li J., Gao H., et al. Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis. Journal of Biomedicine and Biotechnology. 2012;2012:6. doi: 10.1155/2012/535361.535361 - DOI - PMC - PubMed
    1. Smolen J. S., Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Reviews Drug Discovery. 2003;2(6):473–488. doi: 10.1038/nrd1109. - DOI - PubMed
    1. Smolen J. S., Aletaha D., Koeller M., Weisman M. H., Emery P. New therapies for treatment of rheumatoid arthritis. The Lancet. 2007;370(9602):1861–1874. doi: 10.1016/S0140-6736(07)60784-3. - DOI - PubMed
    1. Zhu J., Paul W. E. CD4 T cells: fates, functions, and faults. Blood, The Journal of the American Society of Hematology. 2008;112(5):1557–1569. doi: 10.1182/blood-2008-05-078154. - DOI - PMC - PubMed